Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
2 vaccine
AIDS
CoV
HIV
SARS
anti
immunogenicity
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
24
10
2021
pubmed:
3
4
2022
medline:
30
8
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count. PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used. Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters. Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.
Sections du résumé
BACKGROUND
Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count.
METHODS
PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used.
FINDINGS
Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters.
CONCLUSION
Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.
Identifiants
pubmed: 35366316
pii: 6562777
doi: 10.1093/cid/ciac238
pmc: PMC9047161
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
RNA, Messenger
0
Viral Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e552-e563Investigateurs
Chiara Agrati
(C)
Alessandra Amendola
(A)
Andrea Antinori
(A)
Francesco Baldini
(F)
Rita Bellagamba
(R)
Aurora Bettini
(A)
Licia Bordi
(L)
Veronica Bordoni
(V)
Marta Camici
(M)
Caterina Candela
(C)
Rita Casetti
(R)
Concetta Castilletti
(C)
Carlo Cerini
(C)
Stefania Cicalini
(S)
Francesca Colavita
(F)
Sarah Costantini
(S)
Flavia Cristofanelli
(F)
Alessandro Cozzi Lepri
(A)
Claudia D'Alessio
(C)
Alessia De Angelis
(A)
Federico De Zottis
(F)
Lydia de Pascale
(L)
Massimo Francalancia
(M)
Marisa Fusto
(M)
Roberta Gagliardini
(R)
Paola Gallì
(P)
Enrico Girardi
(E)
Giulia Gramigna
(G)
Germana Grassi
(G)
Elisabetta Grilli
(E)
Susanna Grisetti
(S)
Denise Iafrate
(D)
Simone Lanini
(S)
Daniele Lapa
(D)
Patrizia Lorenzini
(P)
Alessandra Marani
(A)
Erminia Masone
(E)
Ilaria Mastrorosa
(I)
Davide Mariotti
(D)
Stefano Marongiu
(S)
Giulia Matusali
(G)
Valentina Mazzotta
(V)
Silvia Meschi
(S)
Annalisa Mondi
(A)
Stefania Notari
(S)
Sandrine Ottou
(S)
Jessica Paulicelli Luca Pellegrino
(J)
Carmela Pinnetti
(C)
Maria Maddalena Plazzi
(M)
Adriano Possi
(A)
Vincenzo Puro
(V)
Alessandra Sacchi
(A)
Eleonora Tartaglia
(E)
Francesco Vaia
(F)
Alessandra Vergori
(A)
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
AIDS. 2010 Sep 10;24(14):2187-92
pubmed: 20616698
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208751
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Sci Transl Med. 2021 Feb 3;13(579):
pubmed: 33536277
bioRxiv. 2021 Feb 16;:
pubmed: 33619489
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
AIDS. 2021 Nov 15;35(14):2399-2401
pubmed: 34261097
Transplantation. 2021 Nov 1;105(11):e234-e243
pubmed: 34310101
Lancet. 2021 Oct 9;398(10308):1377-1380
pubmed: 34534516
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Lancet HIV. 2021 Sep;8(9):e568-e580
pubmed: 34416193
Ann Intern Med. 1988 Jul 15;109(2):101-5
pubmed: 2968064
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270
pubmed: 34293114
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853